Document Detail

Effect of hepatocyte growth-promoting factors on myocardial ischemia during exercise in patients with severe coronary artery disease.
MedLine Citation:
PMID:  19506333     Owner:  NLM     Status:  MEDLINE    
Hepatocyte growth-promoting factor (pHGF) has the greatest potential as a therapeutic agent for vascular growth factor. The aim of this study was to investigate the effect of pHGF on myocardial ischemia and exercise capacity in patients with severe coronary artery disease (CAD). Forty-nine patients were enrolled for a two week treatment period. Treadmill graded exercise tests with gas analysis were conducted before and after therapy. Serum levels of HGF were significantly elevated after therapy. The degrees of exercise-induced ST segment depression were decreased more significantly in the pHGF group. Similar differences were also found in the maximum heart rate and the maximum heart rate when the ST segment was depressed 1 mm while undergoing the treadmill graded exercise test. Both were increased more significantly in the pHGF group. Total exercise time, systolic blood pressure in the peak of exercise, the length of time that ST segment depression of 1 mm is needed, and total work all were increased in both groups after intervention. Furthermore, total exercise time and total work were increased more significantly in the pHGF group. The levels of HGF increased significantly after pHGF treatment. pHGF could favorably improve exercise-induced myocardial ischemia and enhance exercise capacity in patients with severe CAD.
Ningfu Wang; Guoxin Tong; Jianmin Yang; Zhanlin Zhou; Hao Pan; Yong Huo; Jian Xu; Xingwei Zhang; Feng Ling; Peizhang Li
Related Documents :
9165173 - Reproducibility of the st-segment depression/heart rate analysis of the exercise electr...
19061713 - How to improve noninvasive coronary artery disease diagnostics in premenopausal women? ...
1339223 - Multiparametric evaluation of brain functions in the mongolian gerbil in vivo.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International heart journal     Volume:  50     ISSN:  1349-2365     ISO Abbreviation:  -     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-09     Completed Date:  2009-07-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101244240     Medline TA:  Int Heart J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  291-9     Citation Subset:  IM    
Department of Cardiology, the First People's Hospital of Hangzhou and Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou City, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blood Pressure / drug effects
Cardiovascular Agents / therapeutic use
Coronary Artery Disease / blood,  drug therapy*
Double-Blind Method
Drug Therapy, Combination
Echocardiography, Doppler, Color
Electrocardiography / drug effects*
Exercise Test / drug effects*
Heart Rate / drug effects
Hepatocyte Growth Factor / adverse effects,  blood,  therapeutic use*
Infusions, Intravenous
Middle Aged
Myocardial Ischemia / blood,  drug therapy*
Prospective Studies
Stroke Volume / drug effects
Reg. No./Substance:
0/Cardiovascular Agents; 67256-21-7/Hepatocyte Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of Phase II Cardiac Rehabilitation on Job Stress and Health-Related Quality of Life After Re...
Next Document:  Elevated plasma levels of B-type natriuretic Peptide but not C-reactive protein are associated with ...